ClinicalTrials.gg
TerminatedNCT04572893Updated May 21, 2025Results posted

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

A Phase 2 interventional study of danicamtiv in Primary Familial Dilated Cardiomyopathy, sponsored by Bristol-Myers Squibb. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.

Enrollment
19th of 42
41 · median 37
Started
2020
with 3 others
Phase 2
8 of 64
none open now
Registered
48th of 64
by date
Lead sponsor
2 of 64
Bristol-Myers Squibb

Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 19th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2020, is one of 8 in phase 2, and was the 48th registered.

Cardiomyopathy, Dilated

255 studies on the registry are indexed under Cardiomyopathy, Dilated; 66 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Cardiomyopathy, Dilated studies recruiting now, 30 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 13 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Cardiomyopathy, Dilated with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.

03

Conditions studied

  • Primary Familial Dilated Cardiomyopathy

Keywords

  • Primary dilated cardiomyopathy (DCM)
  • Familial dilated cardiomyopathy (DCM)
  • Myosin Heavy Chain 7 (MYH7)
  • Titin (TTN)
  • MYK-491
  • danicamtiv
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For MYH7 and TTN cohorts, must have diagnosis of primary DCM (dilated cardiomyopathy), clinically stable and due to probably disease-causing variant of MYH7 or TTN
  • Has adequate acoustic windows for echocardiography
  • Maximum of 3 family members with same variant can be enrolled
  • For the cohort of primary DCM due to causalities other than MYH7 and TTN, participant must have diagnosis of primary DCM with a cause not related to MYH7 or TTN variants

Exclusion criteria

Exclusion Criteria:

  • Significant structural cardiac abnormalities including valvar dysfunction on Screening transthoracic echo(s)
  • Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, afterload reduction, or diuretics)
  • Presence of protocol specified laboratory abnormalities at Screening
  • Recent acute coronary syndrome or angina pectoris (\<90 days)
  • Recent hospitalization for heart failure (\<90 days)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    MYK-491

    Primary DCM due to MYH7 or TTN Variant or due to other causalities not related to MYH7 or TTN variants

    Drug: danicamtiv

Interventions

  • Myosin activator

    Also known as: MYK-491, BMS-986434

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) in Part A

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)

  2. Number of Participants With Serious Adverse Events (SAEs) in Part A

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)

  3. Number of Participants With Safety Laboratory Assessments by Intensity in Part A

    Number of participants with safety laboratory assessments by intensity. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities.

    Time frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)

  4. Number of Participants With Clinically Significant Changes in Physical Examinations in Part A

    Number of participants with clinically significant changes in physical examinations.

    Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)

  5. Number of Participants With Clinically Significant Changes in Vital Signs in Part A

    Number of participants with clinically significant changes in vital signs.

    Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)

  6. Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A

    Number of participants with clinically significant changes in 12-lead ECG recordings.

    Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part A

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities. Severe= An event preventing normal everyday activities. (An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.)

    Time frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)

Secondary outcomes

  1. Transthoracic Echo (TTE) Left Ventricular Ejection Time (LVET) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  2. Transthoracic Echo (TTE) Left Ventricular Stroke Volume (LVSV) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  3. Transthoracic Echo (TTE) Left Ventricular Ejection Fraction (LVEF) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination

  4. Transthoracic Echo (TTE) Left Ventricular Global Longitudinal Strain (LVGLS) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination

  5. Transthoracic Echo (TTE) Left Ventricular Global Circumferential Strain (LVGCS) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination

  6. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Lateral Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  7. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Septal Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  8. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Diameter (LVESD) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  9. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Volumen Index (LVESVi) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination

  10. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Diameter (LVEDD) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  11. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Volumen Index (LVEDVi) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination

  12. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Lateral Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  13. Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Septal Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  14. Transthoracic Echo (TTE) E/E Prime Average Ratio Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  15. Transthoracic Echo (TTE) E/E Prime Lateral Ratio Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  16. Transthoracic Echo (TTE) E/E Prime Septal Ratio Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  17. Transthoracic Echo (TTE) Ratio of Peak Inflow Velocities in Early and Late Diastole - E/A Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  18. Transthoracic Echo (TTE) Left Atrial Minimum Volume (LAminV) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  19. Transthoracic Echo (TTE) Left Atrial Maximum Volume Index (LAmaxVi) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  20. Transthoracic Echo (TTE) Left Atrial Emptying Fraction (LAEF) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

  21. Transthoracic Echo (TTE) Left Atrial Function Index (LAFI) Change From Baseline

    Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days. Higher LAFI values are considered better left atrial function while lower LFAI values may indicate left atrial dysfunction.

    Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination

07

Results

Posted May 21, 2025

Participant flow

Part A
Participant flow — Part A
MilestonePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
Started1214510000
Started part b8704000
Completed1114510000
Not completed1000000
Withdrew: Adverse event1000000
Part B
Participant flow — Part B
MilestonePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
Started0000874
Completed0000000
Not completed0000874
Withdrew: Withdrawal by subject0000010
Withdrew: Study terminated by sponsor0000753
Withdrew: Lost to follow-up0000001
Withdrew: Adverse event0000110

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) in Part A

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 30 days post last dose (Up to approximately 15 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Number of Participants With Adverse Events (AEs) in Part A9944
PrimaryNumber of Participants With Serious Adverse Events (SAEs) in Part A

An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first dose to 30 days post last dose (Up to approximately 15 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Number of Participants With Serious Adverse Events (SAEs) in Part A0000
PrimaryNumber of Participants With Safety Laboratory Assessments by Intensity in Part A

Number of participants with safety laboratory assessments by intensity. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities.

Time frame:
From first dose to 14 days post last dose (Up to approximately 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Safety Laboratory Assessments by Intensity in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Alanine aminotransferase increased Mild1010
Aspartate aminotransferase increased Mild1010
Blood creatinine increased Moderate0010
Fibrin D dimer increased Moderate0100
Hyperkalaemia Mild0100
Hyperkalaemia Moderate0010
SecondaryTransthoracic Echo (TTE) Left Ventricular Ejection Time (LVET) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · msec
Transthoracic Echo (TTE) Left Ventricular Ejection Time (LVET) Change From Baseline
msecPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 112.1 ± 23.77.4 ± 28.8-3.5 ± 8.73.3 ± 36.3———
End of treatment period 229.4 ± 31.029.0 ± 25.4-5.6 ± 18.215.2 ± 54.4———
week 2————38.3 ± 30.044.3 ± 16.320.3 ± 34.5
week 6————25.3 ± 22.353.3 ± 43.620.5 ± 67.2
week 12————32.1 ± 27.438.2 ± 33.544.0 ± NA
week 24————39.8 ± 46.359.8 ± 39.5—
week 36—————47.5 ± 9.2—
week 48————42.3 ± 40.330.3 ± 34.0—
Early termination-23.0 ± NA———13.5 ± 44.4-1.4 ± 20.5-14.3 ± 35.2
PrimaryNumber of Participants With Clinically Significant Changes in Physical Examinations in Part A

Number of participants with clinically significant changes in physical examinations.

Time frame:
From first dose to 30 days post last dose (Up to approximately 15 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examinations in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Number of Participants With Clinically Significant Changes in Physical Examinations in Part A0100
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs in Part A

Number of participants with clinically significant changes in vital signs.

Time frame:
From first dose to 30 days post last dose (Up to approximately 15 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Number of Participants With Clinically Significant Changes in Vital Signs in Part A0000
PrimaryNumber of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A

Number of participants with clinically significant changes in 12-lead ECG recordings.

Time frame:
From first dose to 30 days post last dose (Up to approximately 15 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A0000
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part A

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities. Severe= An event preventing normal everyday activities. (An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.)

Time frame:
From first dose to 14 days post last dose (Up to approximately 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part A
ParticipantsPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491
Mild8634
Moderate0110
Severe0000
SecondaryTransthoracic Echo (TTE) Left Ventricular Stroke Volume (LVSV) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · mL
Transthoracic Echo (TTE) Left Ventricular Stroke Volume (LVSV) Change From Baseline
mLPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 110.581 ± 9.8145.628 ± 3.1271.855 ± 7.979-5.897 ± 17.237———
End of treatment period 210.151 ± 19.5851.243 ± 14.2751.050 ± 13.3792.172 ± 20.000———
week 2————15.576 ± 11.932-7.600 ± 14.358-15.678 ± 18.882
week 6————7.778 ± 21.50818.313 ± 14.69716.500 ± NA
week 12————19.410 ± 21.83224.853 ± 18.18122.320 ± NA
week 24————13.893 ± 14.89225.174 ± 24.052—
week 36—————-20.450 ± NA—
week 48————19.070 ± 16.317-6.863 ± 12.464—
Early termination0.650 ± NA———2.684 ± 30.133-11.136 ± 14.5395.533 ± 20.941
SecondaryTransthoracic Echo (TTE) Left Ventricular Ejection Fraction (LVEF) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Reported as:
Mean · percentage
Transthoracic Echo (TTE) Left Ventricular Ejection Fraction (LVEF) Change From Baseline
percentagePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 14.78 ± 7.404.94 ± 7.08-0.75 ± 3.062.47 ± 6.14———
End of treatment period 28.84 ± 6.435.94 ± 6.151.37 ± 5.364.84 ± 10.00———
week 2————5.53 ± 10.314.21 ± 11.035.60 ± 2.12
week 6————3.31 ± 5.85-0.40 ± 7.8314.05 ± 18.03
week 12————2.44 ± 5.391.77 ± 5.267.60 ± NA
week 24————-2.78 ± 0.592.24 ± 8.58—
week 36—————10.80 ± NA—
Week 42—————23.60 ± NA—
week 48————3.85 ± 4.757.12 ± 11.12—
Early termination-3.20 ± NA———-2.94 ± 4.653.99 ± 9.554.13 ± 5.87
SecondaryTransthoracic Echo (TTE) Left Ventricular Global Longitudinal Strain (LVGLS) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Reported as:
Mean · percentage
Transthoracic Echo (TTE) Left Ventricular Global Longitudinal Strain (LVGLS) Change From Baseline
percentagePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-1.41 ± 2.79-0.79 ± 2.31-0.32 ± 2.81-0.36 ± 1.63———
End of treatment period 2-2.05 ± 2.05-1.21 ± 2.23-1.92 ± 2.00-0.95 ± 2.46———
week 2————-1.60 ± 2.59-1.84 ± 1.66-1.80 ± 2.63
week 6————-2.18 ± 2.53-1.90 ± 1.11-3.65 ± 0.49
week 12————-2.34 ± 2.03-2.00 ± 2.34-4.00 ± NA
week 24————0.02 ± 1.25-2.62 ± 2.66—
week 36—————-2.50 ± NA—
Week 42—————-7.70 ± NA—
week 48————-2.77 ± 1.99-4.33 ± 1.30—
Early termination-0.70 ± NA———0.01 ± 2.12-1.31 ± 1.41-1.90 ± 1.81
SecondaryTransthoracic Echo (TTE) Left Ventricular Global Circumferential Strain (LVGCS) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Reported as:
Mean · percentage
Transthoracic Echo (TTE) Left Ventricular Global Circumferential Strain (LVGCS) Change From Baseline
percentagePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-3.62 ± 3.730.58 ± 2.83-4.10 ± 4.070.15 ± 4.47———
End of treatment period 2-4.00 ± 3.17-1.45 ± 3.32-2.08 ± 1.25-0.78 ± 3.87———
week 2————-5.16 ± 4.55-3.00 ± 3.64-3.25 ± 5.30
week 6————-4.07 ± 3.43-4.68 ± 1.11-0.10 ± NA
week 12————-3.80 ± 1.26-0.94 ± 2.650.00 ± NA
week 24————-2.64 ± 4.72-0.88 ± 1.94—
week 36—————-2.60 ± NA—
Week 42—————-6.00 ± NA—
week 48————-4.05 ± 3.13-3.98 ± 3.43—
Early termination0.40 ± NA———0.54 ± 5.50-1.52 ± 2.380.40 ± 5.23
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Lateral Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · cm/s
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Lateral Change From Baseline
cm/sPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.23 ± 1.90-0.12 ± 0.771.15 ± 0.660.22 ± 1.62———
End of treatment period 21.01 ± 1.750.53 ± 1.571.40 ± 1.38-0.10 ± 1.99———
week 2————-0.04 ± 1.62-0.14 ± 0.88-0.95 ± 0.78
week 6————0.34 ± 0.840.08 ± 0.59-0.80 ± NA
week 12————0.57 ± 1.26-0.03 ± 1.29—
week 24————-0.55 ± 1.330.18 ± 0.65—
week 36—————-0.30 ± NA—
week 48————1.25 ± 1.350.10 ± 0.46—
Early termination-2.30 ± NA———0.14 ± 1.430.67 ± 1.39-1.20 ± 0.57
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Septal Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · cm/s
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Septal Change From Baseline
cm/sPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.56 ± 1.050.03 ± 0.500.78 ± 0.630.06 ± 0.66———
End of treatment period 20.53 ± 0.420.20 ± 0.621.04 ± 1.57-0.20 ± 0.94———
week 2————0.24 ± 0.900.06 ± 0.580.20 ± 1.31
week 6————0.95 ± 0.890.50 ± 1.39-0.05 ± 1.34
week 12————0.77 ± 0.83-0.12 ± 0.741.30 ± NA
week 24————0.17 ± 0.530.17 ± 0.97—
week 36—————-1.40 ± NA—
week 48————1.22 ± 1.270.07 ± 1.14—
Early termination0.40 ± NA———0.40 ± 1.530.10 ± 0.770.67 ± 1.00
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Diameter (LVESD) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · mm
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Diameter (LVESD) Change From Baseline
mmPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-0.15 ± 4.07-2.84 ± 3.470.10 ± 1.44-1.77 ± 5.60———
End of treatment period 2-3.14 ± 5.97-5.48 ± 4.83-3.60 ± 3.48-2.20 ± 6.03———
week 2————-0.90 ± 4.25-5.94 ± 3.74-4.43 ± 9.40
week 6————-0.17 ± 6.01-5.93 ± 4.76-2.20 ± NA
week 12————-0.92 ± 4.67-4.18 ± 4.75-1.60 ± NA
week 24————-0.07 ± 6.04-6.12 ± 4.18—
week 36—————-5.80 ± NA—
week 48————2.90 ± 7.07-4.90 ± 3.53—
Early termination-1.50 ± NA———1.33 ± 10.57-0.77 ± 3.86-0.60 ± 5.36
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Volumen Index (LVESVi) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Reported as:
Mean · mL/m^2
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Volumen Index (LVESVi) Change From Baseline
mL/m^2Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-8.3128 ± 9.2045-2.8341 ± 10.66721.5998 ± 2.6613-3.1748 ± 6.3863———
End of treatment period 2-9.0315 ± 10.6354-7.0016 ± 8.8423-1.7459 ± 6.9756-4.3387 ± 8.9773———
week 2————-16.6661 ± 27.1117-6.1675 ± 12.9178-3.7087 ± 2.2142
week 6————-6.8323 ± 14.6055-7.9134 ± 10.2267-13.2403 ± 18.8755
week 12————-5.5205 ± 9.5934-9.9285 ± 14.1805-0.9776 ± NA
week 24————-2.2674 ± 14.6852-6.6309 ± 19.3049—
week 36—————-21.4681 ± 6.5099—
Week 42—————-29.9173 ± NA—
week 48————-13.5827 ± 21.5043-18.4947 ± 12.9649—
Early termination1.2208 ± NA———-2.3523 ± 14.4189-6.7128 ± 15.24402.9170 ± 6.0452
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Diameter (LVEDD) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · mm
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Diameter (LVEDD) Change From Baseline
mmPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.48 ± 3.61-2.49 ± 3.51-0.60 ± 3.91-1.37 ± 5.14———
End of treatment period 2-0.85 ± 4.36-3.12 ± 3.34-3.50 ± 3.84-1.77 ± 4.60———
week 2————-5.11 ± 9.22-3.56 ± 4.03-5.00 ± 7.04
week 6————-1.75 ± 3.34-3.10 ± 2.610.30 ± NA
week 12————-2.09 ± 3.58-0.17 ± 2.640.90 ± NA
week 24————-2.10 ± 2.50-2.86 ± 5.87—
week 36—————-3.10 ± NA—
Week 42—————-1.50 ± NA—
week 48————-3.40 ± 3.64-2.13 ± 3.40—
Early termination3.60 ± NA———-1.97 ± 5.360.46 ± 3.402.70 ± 1.13
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Volumen Index (LVEDVi) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Reported as:
Mean · m1/m2
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Volumen Index (LVEDVi) Change From Baseline
m1/m2Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-7.3006 ± 7.00430.4855 ± 10.82881.3937 ± 3.9810-3.6715 ± 8.4975———
End of treatment period 2-4.3719 ± 11.6238-4.4642 ± 12.9621-1.1050 ± 6.1575-2.1417 ± 12.8270———
week 2————-19.7184 ± 31.0876-6.7773 ± 10.39630.2596 ± 0.0152
week 6————-6.2694 ± 17.5060-12.9208 ± 11.0202-11.4771 ± 18.4933
week 12————-5.2247 ± 11.4301-11.7627 ± 17.16077.4828 ± NA
week 24————-5.9020 ± 20.7779-6.2700 ± 24.3104—
week 36—————-13.0453 ± 5.3813—
Week 42—————-11.8121 ± NA—
week 48————-14.3351 ± 24.7973-18.5657 ± 6.0845—
Early termination-1.6197 ± NA———-7.2323 ± 24.2148-6.7050 ± 17.25818.3887 ± 3.3592
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Lateral Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · cm/s
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Lateral Change From Baseline
cm/sPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.55 ± 1.630.37 ± 2.511.23 ± 1.210.46 ± 3.27———
End of treatment period 20.51 ± 1.500.58 ± 2.972.60 ± 3.38-0.66 ± 2.23———
week 2————0.23 ± 2.770.42 ± 1.47-1.30 ± 1.51
week 6————0.43 ± 1.18-0.14 ± 1.29-1.30 ± 0.99
week 12————0.83 ± 1.99-1.48 ± 2.36-3.20 ± NA
week 24————0.15 ± 1.52-0.40 ± 2.09—
week 36—————-1.80 ± NA—
week 48————2.25 ± 1.89-0.30 ± 1.60—
Early termination-0.60 ± NA———0.20 ± 2.850.37 ± 2.282.23 ± 2.16
SecondaryTransthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Septal Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · cm/s
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Septal Change From Baseline
cm/sPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.75 ± 1.660.26 ± 1.62-0.05 ± 1.35-0.73 ± 1.30———
End of treatment period 2-0.04 ± 0.860.28 ± 1.590.84 ± 1.12-0.32 ± 1.32———
week 2————0.51 ± 1.43-0.84 ± 1.52-0.17 ± 1.12
week 6————0.58 ± 1.12-0.73 ± 1.94-0.10 ± 2.97
week 12————0.60 ± 1.16-0.86 ± 1.231.90 ± NA
week 24————-0.65 ± 0.76-0.75 ± 0.91—
week 36—————-5.10 ± NA—
week 48————1.75 ± 1.32-1.50 ± 1.93—
Early termination0.60 ± NA———1.04 ± 1.650.04 ± 1.251.03 ± 2.58
SecondaryTransthoracic Echo (TTE) E/E Prime Average Ratio Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · E/E prime ratio
Transthoracic Echo (TTE) E/E Prime Average Ratio Change From Baseline
E/E prime ratioPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-2.45 ± 3.160.07 ± 3.67-0.20 ± 4.460.41 ± 3.23———
End of treatment period 2-2.15 ± 2.880.45 ± 2.99-2.16 ± 3.921.03 ± 2.60———
week 2————-1.43 ± 4.37-0.03 ± 4.40-0.03 ± 0.47
week 6————-1.19 ± 4.09-0.15 ± 5.411.25 ± 1.20
week 12————-2.24 ± 1.56-0.47 ± 3.850.60 ± NA
week 24————0.07 ± 4.67-0.66 ± 4.24—
week 36—————10.70 ± NA—
week 48————-4.88 ± 2.38-1.00 ± 3.89—
Early termination-0.90 ± NA———-1.07 ± 3.30-0.51 ± 3.91-0.03 ± 0.93
SecondaryTransthoracic Echo (TTE) E/E Prime Lateral Ratio Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · E/E prime ratio
Transthoracic Echo (TTE) E/E Prime Lateral Ratio Change From Baseline
E/E prime ratioPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-1.29 ± 1.72-0.08 ± 3.68-1.80 ± 5.60-0.49 ± 3.94———
End of treatment period 2-1.14 ± 2.230.12 ± 2.94-3.58 ± 4.880.73 ± 3.93———
week 2————-1.07 ± 2.88-1.00 ± 1.980.77 ± 1.42
week 6————-0.75 ± 4.23-1.34 ± 2.151.80 ± 2.55
week 12————-2.17 ± 2.452.48 ± 5.434.00 ± NA
week 24————-0.45 ± 3.99-0.47 ± 2.94—
week 36—————5.00 ± NA—
week 48————-4.08 ± 3.06-1.47 ± 1.44—
Early termination0.20 ± NA———-0.91 ± 3.390.75 ± 5.920.10 ± 0.62
SecondaryTransthoracic Echo (TTE) E/E Prime Septal Ratio Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · E/E prime ratio
Transthoracic Echo (TTE) E/E Prime Septal Ratio Change From Baseline
E/E prime ratioPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-3.12 ± 4.51-0.91 ± 3.780.65 ± 2.891.86 ± 2.30———
End of treatment period 2-1.45 ± 2.140.07 ± 4.00-1.38 ± 2.821.32 ± 3.07———
week 2————-1.77 ± 6.751.50 ± 9.41-0.83 ± 1.57
week 6————-1.27 ± 4.431.33 ± 10.610.65 ± 0.07
week 12————-2.27 ± 3.53-1.30 ± 3.68-2.70 ± NA
week 24————0.70 ± 5.41-2.03 ± 7.68—
week 36—————16.50 ± NA—
week 48————-5.68 ± 4.890.05 ± 7.37—
Early termination-2.00 ± NA———-1.19 ± 3.67-1.19 ± 4.95-0.27 ± 2.20
SecondaryTransthoracic Echo (TTE) Ratio of Peak Inflow Velocities in Early and Late Diastole - E/A Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · E/A ratio
Transthoracic Echo (TTE) Ratio of Peak Inflow Velocities in Early and Late Diastole - E/A Change From Baseline
E/A ratioPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 10.02 ± 0.16-0.01 ± 0.32-0.10 ± 0.100.04 ± 0.11———
End of treatment period 2-0.16 ± 0.40-0.08 ± 0.37-0.26 ± 0.54-0.04 ± 0.15———
week 2————0.07 ± 0.92-0.32 ± 0.40-0.12 ± 0.21
week 6————-0.25 ± 0.45-0.58 ± 0.770.15 ± 0.21
week 12————-0.23 ± 0.50-0.76 ± 0.700.20 ± NA
week 24————0.00 ± 0.10-0.53 ± 0.78—
week 36—————0.20 ± NA—
week 48————-0.40 ± 0.52-0.77 ± 0.85—
Early termination0.70 ± NA———-0.10 ± 0.32-0.37 ± 0.520.17 ± 0.06
SecondaryTransthoracic Echo (TTE) Left Atrial Minimum Volume (LAminV) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · mL
Transthoracic Echo (TTE) Left Atrial Minimum Volume (LAminV) Change From Baseline
mLPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-2.545 ± 4.182-0.374 ± 8.947-3.663 ± 9.552-0.563 ± 3.670———
End of treatment period 2-3.985 ± 5.6810.049 ± 8.529-3.993 ± 5.672-2.866 ± 6.613———
week 2————0.509 ± 11.279-3.807 ± 9.9172.817 ± 8.224
week 6————3.430 ± 9.313-10.938 ± 22.8211.680 ± 5.374
week 12————-3.409 ± 13.577-13.953 ± 24.7989.950 ± NA
week 24————-2.858 ± 16.826-5.214 ± 32.177—
week 36—————-16.410 ± NA—
Week 42—————-27.640 ± NA—
week 48————-7.560 ± 7.287-19.843 ± 24.404—
Early termination12.030 ± NA———1.313 ± 13.248-4.793 ± 19.02710.607 ± 3.279
SecondaryTransthoracic Echo (TTE) Left Atrial Maximum Volume Index (LAmaxVi) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · mL/m^2
Transthoracic Echo (TTE) Left Atrial Maximum Volume Index (LAmaxVi) Change From Baseline
mL/m^2Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 1-0.6427 ± 5.00070.9860 ± 7.1462-0.6320 ± 9.1208-0.0084 ± 2.4459———
End of treatment period 2-0.3419 ± 4.23651.1617 ± 6.0815-1.1870 ± 7.2047-0.2139 ± 2.5533———
week 2————0.1346 ± 6.4456-0.1818 ± 5.18022.3315 ± 9.2253
week 6————1.1887 ± 4.2647-5.5545 ± 13.4164-0.5969 ± 10.1570
week 12————-1.9834 ± 9.0618-7.1717 ± 14.86847.8293 ± NA
week 24————-2.3145 ± 11.3192-1.8423 ± 17.8500—
week 36—————-13.3385 ± 3.1173—
Week 42—————-11.7208 ± NA—
week 48————-2.4524 ± 3.4679-11.2887 ± 15.6892—
Early termination8.1892 ± NA———-0.0097 ± 6.8537-1.4975 ± 9.74546.5957 ± 3.9106
SecondaryTransthoracic Echo (TTE) Left Atrial Emptying Fraction (LAEF) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · Percent change
Transthoracic Echo (TTE) Left Atrial Emptying Fraction (LAEF) Change From Baseline
Percent changePart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 15.617 ± 13.4594.675 ± 12.1732.687 ± 26.9132.489 ± 10.953———
End of treatment period 215.504 ± 18.2349.870 ± 15.0198.102 ± 21.5139.655 ± 14.789———
week 2————-1.903 ± 19.04215.609 ± 10.7591.058 ± 6.753
week 6————-9.410 ± 20.95021.196 ± 24.108-7.265 ± 24.267
week 12————5.089 ± 17.89824.306 ± 30.693-6.694 ± NA
week 24————6.522 ± 23.63519.181 ± 31.252—
week 36—————2.595 ± NA—
Week 42—————43.996 ± NA—
week 48————23.815 ± 26.49427.568 ± 24.279—
Early termination-7.060 ± NA———-0.711 ± 30.27611.267 ± 25.412-6.924 ± 11.148
SecondaryTransthoracic Echo (TTE) Left Atrial Function Index (LAFI) Change From Baseline

Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days. Higher LAFI values are considered better left atrial function while lower LFAI values may indicate left atrial dysfunction.

Time frame:
Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Reported as:
Mean · Index
Transthoracic Echo (TTE) Left Atrial Function Index (LAFI) Change From Baseline
IndexPart A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Part B - MYH7 - MYK-491Part B - TTN - MYK-491Part B - DCM-Non Genetic - MYK-491
End of treatment period 15.2299 ± 5.38471.6645 ± 11.9891-0.4600 ± 1.67210.3524 ± 5.0864———
End of treatment period 211.1434 ± 10.52876.8482 ± 13.28051.6243 ± 5.58033.6366 ± 6.4861———
week 2————4.1989 ± 10.09375.6654 ± 7.6211-10.2619 ± 21.2810
week 6————0.7215 ± 23.00689.9039 ± 8.99991.3624 ± 15.4676
week 12————5.3578 ± 14.53828.4149 ± 7.3469-22.1266 ± NA
week 24————-4.8648 ± 19.37248.1890 ± 8.8584—
week 36—————8.6083 ± 8.6083—
week 48————6.3041 ± 18.454312.8222 ± 14.0703—
Early termination-11.0849 ± NA———0.3925 ± 23.93502.4252 ± 10.4948-20.4736 ± 4.7293

Adverse events

Collected over All-cause mortality, serious adverse events, and other adverse events are from first dose until the end of the study visit for the participant (Up to approximately 115 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - MYH7 - MYK-491 25 mg BID0/12 (0%)0/12 (0%)5/12 (41.7%)
Part A - TTN - MYK-491 25 mg BID0/14 (0%)0/14 (0%)3/14 (21.4%)
Part A - DCM-Genetic - MYK-491 25 mg BID0/5 (0%)0/5 (0%)1/5 (20%)
Part A - DCM-Non Genetic - MYK-491 25 mg BID0/10 (0%)0/10 (0%)2/10 (20%)
Part A - MYH7 - MYK-491 50 mg BID0/12 (0%)0/12 (0%)5/12 (41.7%)
Part A - TTN - MYK-491 50 mg BID0/14 (0%)0/14 (0%)5/14 (35.7%)
Part A - DCM-Genetic - MYK-491 50 mg BID0/4 (0%)0/4 (0%)2/4 (50%)
Part A - DCM-Non Genetic - MYK-491 50 mg BID0/9 (0%)0/9 (0%)2/9 (22.2%)
Part A - DCM-Genetic - MYK-491 10 mg BID0/1 (0%)0/1 (0%)0/1 (0%)
Part A - DCM-Non Genetic - MYK-491 10 mg BID0/1 (0%)0/1 (0%)0/1 (0%)
Part B - MYH7 - MYK-491 25 mg BID0/1 (0%)0/1 (0%)1/1 (100%)
Part B - MYH7 - MYK-491 50 mg BID0/4 (0%)1/4 (25%)3/4 (75%)
Part B - TTN - MYK-491 50 mg BID0/4 (0%)1/4 (25%)3/4 (75%)
Part B - DCM-Non Genetic - MYK-491 50 mg BID0/1 (0%)0/1 (0%)0/1 (0%)
Part B - MYH7 - MYK-491 75 mg BID0/5 (0%)0/5 (0%)5/5 (100%)
Part B - TTN - MYK-491 75 mg BID0/4 (0%)2/4 (50%)4/4 (100%)
Part B - DCM-Non Genetic - MYK-491 75 mg BID0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventPart A - MYH7 - MYK-491 25 mg BIDPart A - TTN - MYK-491 25 mg BIDPart A - DCM-Genetic - MYK-491 25 mg BIDPart A - DCM-Non Genetic - MYK-491 25 mg BIDPart A - MYH7 - MYK-491 50 mg BIDPart A - TTN - MYK-491 50 mg BIDPart A - DCM-Genetic - MYK-491 50 mg BIDPart A - DCM-Non Genetic - MYK-491 50 mg BIDPart A - DCM-Genetic - MYK-491 10 mg BIDPart A - DCM-Non Genetic - MYK-491 10 mg BIDPart B - MYH7 - MYK-491 25 mg BIDPart B - MYH7 - MYK-491 50 mg BIDPart B - TTN - MYK-491 50 mg BIDPart B - DCM-Non Genetic - MYK-491 50 mg BIDPart B - MYH7 - MYK-491 75 mg BIDPart B - TTN - MYK-491 75 mg BIDPart B - DCM-Non Genetic - MYK-491 75 mg BID
Cardiac failure congestiveCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/50/41/3
Arrhythmic stormCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3
Ventricular fibrillationCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3
Liver injuryHepatobiliary disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3
Urinary tract infectionInfections and infestations0/120/140/50/100/120/140/40/90/10/10/11/40/40/10/50/40/3
Transient ischaemic attackNervous system disorders0/120/140/50/100/120/140/40/90/10/10/10/41/40/10/50/40/3
Acute kidney injuryRenal and urinary disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3
Most frequent other events
Showing 10 of 75
Most frequent other events
EventPart A - MYH7 - MYK-491 25 mg BIDPart A - TTN - MYK-491 25 mg BIDPart A - DCM-Genetic - MYK-491 25 mg BIDPart A - DCM-Non Genetic - MYK-491 25 mg BIDPart A - MYH7 - MYK-491 50 mg BIDPart A - TTN - MYK-491 50 mg BIDPart A - DCM-Genetic - MYK-491 50 mg BIDPart A - DCM-Non Genetic - MYK-491 50 mg BIDPart A - DCM-Genetic - MYK-491 10 mg BIDPart A - DCM-Non Genetic - MYK-491 10 mg BIDPart B - MYH7 - MYK-491 25 mg BIDPart B - MYH7 - MYK-491 50 mg BIDPart B - TTN - MYK-491 50 mg BIDPart B - DCM-Non Genetic - MYK-491 50 mg BIDPart B - MYH7 - MYK-491 75 mg BIDPart B - TTN - MYK-491 75 mg BIDPart B - DCM-Non Genetic - MYK-491 75 mg BID
NasopharyngitisInfections and infestations0/120/140/50/101/120/140/40/90/10/11/10/41/40/11/51/40/3
COVID-19Infections and infestations0/120/140/50/101/120/140/40/90/10/10/10/42/40/10/51/41/3
Respiratory tract infectionInfections and infestations0/120/140/50/100/120/140/40/90/10/10/11/42/40/11/50/40/3
HypotensionVascular disorders0/120/140/50/100/120/140/40/90/10/10/11/40/40/10/52/41/3
FatigueGeneral disorders2/120/140/50/101/120/140/40/90/10/10/10/40/40/11/51/41/3
Atrial flutterCardiac disorders0/120/140/50/100/120/140/40/90/10/10/11/40/40/10/50/40/3
Cardiac failureCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/41/40/10/51/40/3
PalpitationsCardiac disorders1/120/140/50/100/120/140/40/90/10/10/11/40/40/10/50/40/3
Ventricular extrasystolesCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3
Ventricular tachycardiaCardiac disorders0/120/140/50/100/120/140/40/90/10/10/10/40/40/10/51/40/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Total
<=18 years00000
Between 18 and 65 years11124936
>=65 years12115
Sex: Female, Male
Sex: Female, Male(Participants)Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Total
Female742215
Male5103826
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Total
Hispanic or Latino31105
Not Hispanic or Latino91331035
Unknown or Not Reported00101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - MYH7 - MYK-491Part A - TTN - MYK-491Part A - DCM-Genetic - MYK-491Part A - DCM-Non Genetic - MYK-491Total
Asian10001
American Indian or Alaska Native00000
Black or African American00022
Native Hawaiian or other Pacific Islander00000
White11145838
Uknown00000
08

Study locations

19 sites
  • Local Institution - 0007
    La Jolla, California 92037, United States
  • Local Institution - 0010
    Washington, District of Columbia 20007, United States
  • Local Institution - 0009
    Tampa, Florida 33612, United States
  • Local Institution - 0002
    Chicago, Illinois 60611-5966, United States
  • Local Institution - 0003
    Boston, Massachusetts 02115, United States
  • Local Institution - 0005
    Rochester, Minnesota 55905, United States
  • Local Institution - 0006
    Cleveland, Ohio 44195-0001, United States
  • Local Institution - 0019
    Columbus, Ohio 43210, United States
  • Local Institution - 0001
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0004
    Charleston, South Carolina 29425, United States
  • Local Institution - 0008
    Germantown, Tennessee 38138, United States
  • Local Institution - 0018
    Austin, Texas 78705, United States
  • Local Institution - 0014
    Heidelberg, Baden-Württemberg 69120, Germany
  • Local Institution - 0015
    Wuerzburg, 97080, Germany
  • Local Institution - 0012
    A Coruña, 15006, Spain
  • Local Institution - 0011
    El Palmar, 30120, Spain
  • Local Institution - 0013
    Majadahonda, 28222, Spain
  • Local Institution - 0016
    London, EC1A 7BE, United Kingdom
  • Local Institution - 0017
    Middlesex, UB9 6JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Feb 2024, 42 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Oct 1, 2020
StartActual
Aug 4, 2020
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 22, 2024
Results first posted
May 21, 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04572893
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Aug 4, 2020
Primary completion
Feb 22, 2024
Completion
Feb 22, 2024
Results posted
May 21, 2025
Last update
May 21, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicamtiv

Start the discussion